311 related articles for article (PubMed ID: 21300850)
1. Barth syndrome mutations that cause tafazzin complex lability.
Claypool SM; Whited K; Srijumnong S; Han X; Koehler CM
J Cell Biol; 2011 Feb; 192(3):447-62. PubMed ID: 21300850
[TBL] [Abstract][Full Text] [Related]
2. Seven functional classes of Barth syndrome mutation.
Whited K; Baile MG; Currier P; Claypool SM
Hum Mol Genet; 2013 Feb; 22(3):483-92. PubMed ID: 23100323
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of branched-chain amino acid aminotransferases rescues the growth defects of cells lacking the Barth syndrome-related gene TAZ1.
Antunes D; Chowdhury A; Aich A; Saladi S; Harpaz N; Stahl M; Schuldiner M; Herrmann JM; Rehling P; Rapaport D
J Mol Med (Berl); 2019 Feb; 97(2):269-279. PubMed ID: 30604168
[TBL] [Abstract][Full Text] [Related]
4. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
5. Defining functional classes of Barth syndrome mutation in humans.
Lu YW; Galbraith L; Herndon JD; Lu YL; Pras-Raves M; Vervaart M; Van Kampen A; Luyf A; Koehler CM; McCaffery JM; Gottlieb E; Vaz FM; Claypool SM
Hum Mol Genet; 2016 May; 25(9):1754-70. PubMed ID: 26908608
[TBL] [Abstract][Full Text] [Related]
6. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome.
Claypool SM; Boontheung P; McCaffery JM; Loo JA; Koehler CM
Mol Biol Cell; 2008 Dec; 19(12):5143-55. PubMed ID: 18799610
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins.
Claypool SM; McCaffery JM; Koehler CM
J Cell Biol; 2006 Jul; 174(3):379-90. PubMed ID: 16880272
[TBL] [Abstract][Full Text] [Related]
8. Tafazzin splice variants and mutations in Barth syndrome.
Kirwin SM; Manolakos A; Barnett SS; Gonzalez IL
Mol Genet Metab; 2014 Jan; 111(1):26-32. PubMed ID: 24342716
[TBL] [Abstract][Full Text] [Related]
9. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
10. Cardiolipin deficiency leads to the destabilization of mitochondrial magnesium channel MRS2 in Barth syndrome.
Joshi A; Gohil VM
Hum Mol Genet; 2023 Dec; 32(24):3353-3360. PubMed ID: 37721533
[TBL] [Abstract][Full Text] [Related]
11. The Taz1p transacylase is imported and sorted into the outer mitochondrial membrane via a membrane anchor domain.
Herndon JD; Claypool SM; Koehler CM
Eukaryot Cell; 2013 Dec; 12(12):1600-8. PubMed ID: 24078306
[TBL] [Abstract][Full Text] [Related]
12. The mitochondrial quality control protein Yme1 is necessary to prevent defective mitophagy in a yeast model of Barth syndrome.
Gaspard GJ; McMaster CR
J Biol Chem; 2015 Apr; 290(14):9284-98. PubMed ID: 25688091
[TBL] [Abstract][Full Text] [Related]
13. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
14. Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome.
Brandner K; Mick DU; Frazier AE; Taylor RD; Meisinger C; Rehling P
Mol Biol Cell; 2005 Nov; 16(11):5202-14. PubMed ID: 16135531
[TBL] [Abstract][Full Text] [Related]
15. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
16. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
17. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
18. Blocking phosphatidylglycerol degradation in yeast defective in cardiolipin remodeling results in a new model of the Barth syndrome cellular phenotype.
Káňovičová P; Čermáková P; Kubalová D; Bábelová L; Veselá P; Valachovič M; Zahumenský J; Horváth A; Malínský J; Balážová M
J Biol Chem; 2022 Jan; 298(1):101462. PubMed ID: 34864056
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
20. Mis-sesnse mutations in Tafazzin (TAZ) that escort to mild clinical symptoms of Barth syndrome is owed to the minimal inhibitory effect of the mutations on the enzyme function: In-silico evidence.
Debnath S; Addya S
Interdiscip Sci; 2015 Mar; 7(1):21-35. PubMed ID: 25118650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
